Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases - Trial NCT06401824
Access comprehensive clinical trial information for NCT06401824 through Pure Global AI's free database. This Phase 2 trial is sponsored by Maastricht University Medical Center and is currently Not yet recruiting. The study focuses on NSCLC Stage IV,Brain Metastases, Adult. Target enrollment is 25 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab
Interventional
drug
Sponsor & Location
Maastricht University Medical Center
Timeline & Enrollment
Phase 2
Jul 01, 2024
Apr 01, 2027
Primary Outcome
brain metastases overall response rate (ORR)
Summary
This study will evaluate whether the combination of sacituzumab govitecan (SG) and
 bevacizumab will result in shrinkage of brain metastases from patients with non-squamous
 non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and
 immunotherapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06401824
Non-Device Trial